Summary & Overview
HCPCS J7340: Carbidopa/Levodopa Enteral Suspension, 100 ml
HCPCS Level II code J7340 identifies a 100 ml enteral suspension of carbidopa 5 mg/levodopa 20 mg. This code covers the supply of a liquid antiparkinsonian medication formulated for enteral delivery, a clinically important option for patients who cannot tolerate or safely use oral solid-dose formulations. Nationally, the code matters for inpatient, long-term care, and post-acute billing because enteral formulations can affect medication administration workflows, pharmacy dispensing, and cost of care for patients with advanced Parkinson disease.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context for use of the enteral suspension, typical sites of service where billing occurs, and an overview of billing considerations tied to this HCPCS Level II code. The publication provides benchmarks and policy-oriented discussion relevant to coverage and coding practices, plus practical notes on documentation elements commonly required by payers.
The report is aimed at coders, revenue cycle staff, pharmacy billing professionals, and clinical teams involved in enteral medication management. It summarizes what to expect when billing for this product, highlights where documentation intersects with payer review, and outlines the clinical rationale for selecting an enteral carbidopa/levodopa formulation.
Billing Code Overview
HCPCS Level II code J7340 represents carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml. The service is the provision of a ready-to-administer enteral suspension formulation of carbidopa/levodopa used for management of Parkinsonian symptoms when oral administration is not feasible or when enteral delivery is clinically indicated. The service type is medication administration/supply of a liquid enteral antiparkinsonian agent. The typical site of service is inpatient hospital units, long-term care facilities, and other settings where enteral medication delivery (via feeding tube) is used.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with advanced Parkinson disease experiencing motor fluctuations and dysphagia who requires enteral levodopa/carbidopa delivery via a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) or an existing enteral feeding tube. The pharmacy dispenses J7340 — carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml — for continuous or scheduled enteral administration when oral intake is unreliable or when intrajejunal infusion is used for optimized motor control.
Clinical workflow: the neurologist documents the indication and dosing plan; the interventional gastroenterologist places or confirms patency of the enteral tube (if needed); the home infusion or specialty pharmacy prepares and dispenses J7340 in 100 ml units; nursing or a trained caregiver administers the suspension via the enteral tube according to the prescribed infusion schedule; regular follow-up with neurology monitors symptom control, dosing adjustments, and adverse effects. Supply ordering, billing, and prior authorization are managed by the clinic or pharmacy prior to shipment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office or other outpatient visit | Use when the drug is billed in conjunction with an outpatient visit where the visit is the primary service and the drug is separately billed. |